The Federal Trade Commission on July 14 finalized a landmark settlement with CVS Caremark, the pharmacy benefit manager accused of artificially inflating insulin prices, the second such settlement the agency has secured in the Biden-Trump era’s most aggressive antitrust push into prescription drug middlemen.
The settlement, approved by FTC Chairman Andrew Ferguson in a 1-0-1 vote (Commissioner Melissa Meador recused), requires CVS Caremark to fundamentally restructure how it does business. The projected benefit to patients: up to $8.5 billion in out-of-pocket savings over 10 years, with $4.5 billion of that specifically from requiring rebates to be passed through at the point of sale.
What the settlement requires
CVS Caremark must implement several structural reforms:
- Fee delinking: Pharmacy benefit manager (PBM) compensation can no longer be tied to a drug’s list price, removing the incentive to favor high-priced drugs with large rebates.
- Non-discrimination: Caremark must stop excluding lower-list-price insulins from its formularies.
- Rebate-free formulary: Plan sponsors must be offered a standard formulary that excludes rebates entirely, giving employers and insurers a transparent alternative.
- TrumpRx compatibility: Patient purchases on the TrumpRx platform must count toward their deductibles.
- Pharmacy hub protections: CVS cannot interfere with pharmacies that use rival hub service providers, a response to allegations that CVS used its control of prescription fulfillment to steer patients to its own pharmacies.
- Insulin price cap: CVS committed to making insulin available at $25 per month through its ReducedRx program, which covers 60,000-plus pharmacies.
A compliance monitor will be appointed to oversee implementation.
The allegations the case rests on
The FTC’s original complaint, filed in September 2024, alleged that Caremark, along with Express Scripts (Cigna) and OptumRx (UnitedHealth Group), created a “chase-the-rebate” system that systematically excluded lower-list-price insulins from formularies while shifting cost burdens to patients through deductibles and coinsurance tied to inflated list prices. The three PBMs control approximately 80% of all U.S. prescriptions.
The complaint noted that Humalog’s list price rose more than 1,200% from $21 in 1999 to over $274 in 2017, and Novolog rose 136% from $122.59 in 2012 to $289.36 in 2018. By 2019, one in four insulin patients could not afford their medication.
The FTC alleged that PBMs kept hundreds of millions of dollars annually in rebates from drug manufacturers, creating a system where list prices spiraled upward while the actual net price may have remained flat, but patients, who often pay a percentage of list price through coinsurance, bore the full weight of the increases.
The chain of settlements
The CVS agreement follows a $7 billion settlement with Express Scripts in February 2026. OptumRx, the third PBM named in the original complaint, was withdrawn from the administrative adjudication in June 2026 to consider a proposed consent agreement, its settlement remains pending.
CVS responds
CVS Health responded positively to the agreement. Ed DeVaney, Executive Vice President of CVS Health and President of CVS Caremark, stated: “Today’s agreement advances and reinforces the changes we have already put in place and ensures affordability for families and patients across the country.”
CVS noted that it had already negotiated approximately $80 billion in savings for clients and members in the past year, and that its $25/month insulin affordability program was already available to members. The company framed the settlement as a formalization of changes it had been implementing voluntarily.
Why it matters
The settlement is significant not just for insulin prices but as a precedent for how the PBM industry can be restructured. Fee delinking, the core of the settlement, directly attacks the perverse incentive that the FTC identified as the root cause of high drug list prices. By prohibiting PBMs from profiting from the gap between list price and net price, the model removes the financial motivation to prefer high-list-price drugs.
If OptumRx signs a similar settlement, all three major PBMs will be operating under consent decrees that fundamentally alter their business model, a transformation of the U.S. drug pricing infrastructure that would have seemed unlikely five years ago.
What’s still unknown
The settlement imposes no cash penalty on CVS Caremark. Critics may argue that structural reforms without financial penalties do not adequately address the harm done to patients who paid inflated prices for years. Additionally, the savings projections, while endorsed by the FTC, depend on behavioral responses from drug manufacturers, insurers, and employers that are not guaranteed.
The $8.5 billion figure is the FTC’s upper-bound estimate of potential consumer savings. Whether it materializes depends on how aggressively plan sponsors adopt the new rebate-free formularies and how manufacturers respond to the changed incentive structure.
Source
1. Federal Trade Commission. (2026, July 14). FTC Secures Major Settlement with Caremark, Resolving Antitrust Case Against Second Drug Middleman. https://www.ftc.gov/news-events/news/press-releases/2026/07/ftc-secures-major-settlement-caremark-resolving-antitrust-case-against-second-drug-middleman
2. CVS Health. (2026, July 14). CVS Caremark announces agreement with FTC to further advance industry-leading approaches to transparency and affordability. https://www.cvshealth.com/news/company-news/cvs-caremark-announces-agreement-with-ftc.html
3. Silverman, E. (2026, July 14). FTC settles lawsuit with CVS Caremark over manipulated insulin prices. STAT News. https://www.statnews.com/pharmalot/2026/07/14/ftc-settles-lawsuit-cvs-caremark-insulin-prices-access/